Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia

Journal of Internal Medicine

Volumn 269, Issue 5, 2011, Pages 496-506

  Gilden, D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Immunization; Postherpetic neuralgia; Shingles; Zoster

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; CHICKENPOX VACCINE; FOSCARNET; GANCICLOVIR; PLACEBO; STEROID; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ABDOMINAL PAIN; ADULT; AGED; ANTIVIRAL THERAPY; AWARENESS; BRAIN INFECTION; CANADA; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; ELDERLY CARE; ERYTHEMA; EYE DISEASE; HEAT; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; MENINGOENCEPHALITIS; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SALIVARY GLAND PAIN; SIDE EFFECT; SPINAL CORD DISEASE; STOMACH PAIN; STROKE; UNITED KINGDOM; UNITED STATES; VARICELLA ZOSTER VIRUS; VASCULAR DISEASE; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LATENCY; VIRUS MENINGITIS; VIRUS PATHOGENESIS; VIRUS REACTIVATION; ZOSTER SINE HERPETE;

AGED; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MIDDLE AGED; NEURALGIA, POSTHERPETIC; VACCINES, ATTENUATED;

EID: 79954970198     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02359.x     Document Type: Review

References (102)

1. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-9.
2. Leppard B, Naburi AE. Herpes zoster: an early manifestation of HIV infection. Afr Health 1998; 21: 5-6.
3. Kakourou T, Theodoridou M, Mostrou G, Syriopoulou V, Papadogeorgaki H, Constantopoulos A. Herpes zoster in children. J Am Acad Dermatol 1998; 39: 207-10.
4. Gallagher JG, Merigan TC. Prolonged herpes-zoster infection associated with immunosuppressive therapy. Ann Intern Med 1979; 91: 842-6.
5. Blumenthal DT, Salzman KL, Baringer JR, Forghani B, Gilden DH. MRI abnormalities in chronic active varicella zoster infection. Neurology 2004; 63: 1538-9.
6. Carroll WM, Mastaglia FL. Optic neuropathy and ophthalmoplegia in herpes zoster oticus. Neurology 1979; 29: 726-9.
7. Garty B-Z, Dinari G, Sarnat H, Cohen S, Nitzan M. Tooth exfoliation and osteonecrosis of the maxilla after trigeminal herpes zoster. J Pediatr 1985; 106: 71-3.
8. Manz HJ, Canter HG, Melton J. Trigeminal herpes zoster causing mandibular osteonecrosis and spontaneous tooth exfoliation. South Med J 1986; 79: 1026-8.
9. Robillard RB, Hilsinger RL Jr, Adour KK. Ramsay Hunt facial paralysis: clinical analyses of 185 patients. Otolaryngol Head Neck Surg 1986; 95: 292-7.
10. Asnis DS, Micic L, Giaccio D. Ramsay Hunt syndrome presenting as a cranial polyneuropathy. Cutis 1996; 57: 421-4.
11. Archambault P, Wise JS, Rosen J, Polomeno RC, Auger N. Herpes zoster ophthalmoplegia. Report of six cases. J Clin Neuroophthalmol 1998; 8: 185-93.
12. Meenken C, van den Horn GJ, de Smet MD, van der Meer JT. Optic neuritis heralding varicella zoster virus retinitis in a patient with acquired immunodeficiency syndrome. Ann Neurol 1998; 43: 534-6.
13. Sodhi PK, Goel JL. Presentations of cranial nerve involvement in two patients with herpes zoster ophthalmicus. J Commun Dis 2001; 33: 130-5.
14. Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71: 149-54.
15. Volvoikar P, Patil S, Dinkar A. Tooth exfoliation, osteonecrosis and neuralgia following herpes zoster of trigeminal nerve. Indian J Dent Res 2002; 13: 11-4.
16. Furuta Y, Ohtani F, Aizawa H, Fukuda S, Kawabata H, Bergström T. Varicella-zoster virus reactivation is an important cause of acute peripheral facial paralysis in children. Pediatr Infect Dis J 2005; 24: 97-101.
17. Karmon Y, Gadath N. Delayed oculomotor nerve palsy after bilateral cervical zoster in an immunocompetent patient. Neurology 2005; 65: 170.
18. Merchet MP, Gruener G. Segmental zoster paresis of limbs. Electromyogr Clin Neurophysiol 1996; 36: 369-75.
19. Yoleri O, Olmez N, Oztura I, Sengül I, Günaydin R, Memis A. Segmental zoster paresis of the upper extremity: a case report. Arch Phys Med Rehabil 2005; 86: 1492-4.
20. Anderson JP, Keal EE. Cervical herpes zoster and diaphragmatic paralysis. Br J Dis Chest 1969; 63: 222-6.
21. Tjandra J, Mansel RE. Segmental abdominal herpes zoster paresis. Aust N Z J Surg 1986; 56: 807-8.
22. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 2004; 72: 174-9.
23. Cohrs RJ, Mehta SK, Schmid DS, Gilden DH, Pierson DL. Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol 2008; 80: 1116-22.
24. Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23: 353-523.
25. Denny-Brown D, Adams RD, Fitzgerald PJ. Pathologic features of herpes zoster: a note on "geniculate herpes". Arch Neurol Psychiatr 1944; 51: 216-31.
26. Cheatham WJ, Dolan TF Jr, Dower JC, Weller TH. Varicella: report on two fatal cases with necropsy, virus isolation, and serologic studies. Am J Pathol 1956; 32: 1015-35.
27. Esiri MM, Tomlinson AH. Herpes zoster: demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J Neurol Sci 1972; 15: 35-48.
28. Ghatak NR, Zimmerman HM. Spinal ganglion in herpes zoster. Arch Pathol 1973; 95: 411-5.
29. Nagashima K, Nakazawa M, Endo H. Pathology of the human spinal ganglia in varicella-zoster virus infection. Acta Neuropathol 1975; 33: 105-17.
30. Rogers RS III, Tindall JP. Herpes zoster in the elderly. Postgrad Med 1971; 50: 153-7.
31. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327-31.
32. Watson CPN, Morshead C, Van der Kooy D, Deck JH, Evans RJ. Postherpetic neuralgia: post-mortem analysis of a case. Pain 1988; 34: 129-38.
33. Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Postherpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991; 44: 105-17.
34. Vafai A, Wellish M, Gilden DH. Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia. Proc Natl Acad Sci USA 1988; 85: 2767-70.
35. Devlin ME, Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis 1992; 165: 619-22.
36. Mahalingam R, Wellish M, Brucklier J, Gilden DH. Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol 1995; 1: 130-3.
37. Terada K, Niizuma T, Kawano S, Kataoka N, Akisada T, Orita Y. Detection of varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt syndrome or zoster sine herpete. J Med Virol 1998; 56: 359-63.
38. Gilden DH, Cohrs RJ, Hayward AR, Wellish M, Mahalingam R. Chronic varicella zoster virus ganglionitis - a possible cause of postherpetic neuralgia. J Neurovirol 2003; 9: 404-7.
39. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol 2006; 63: 940-2.
40. O'Donohue JM, Enzmann DR. Mycotic aneurysm in angiitis associated with herpes zoster ophthalmicus. Am J Neuroradiol 1987; 8: 615-9.
41. Bhayani N, Ranade P, Clark NM, McGuinn M. Varicella-zoster virus and cerebral aneurysm: case report and review of the literature. Clin Infect Dis 2008; 47: e1-3.
42. Nagel MA, Cohrs RJ, Mahalingam R et al. The varicella zoster vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008; 70: 853-60.
43. Burgoon MP, Hammack BN, Owens GP, Maybach AL, Eikelenboom MJ, Gilden DH. Oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV. Ann Neurol 2003; 54: 459-63.
44. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009; 40: 3443-8.
45. Lin H-C, Chien C-W, Ho J-D. Herpes zoster ophthalmicus and the risk of stroke: a population-based follow-up study. Neurology 2010; 74: 792-7.
46. Nagel MA, Forghani B, Mahalingam R et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology 2007; 68: 1069-73.
47. Hilt DC, Buchholz D, Krumholz A, Weiss H, Wolinsky JS. Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol 1983; 14: 543-53.
48. Gilden DH, Lipton HL, Wolf JS et al. Two patients with unusual forms of varicella-zoster virus vasculopathy. N Engl J Med 2002; 347: 1500-3.
49. Gilden DH. Varicella zoster virus vasculopathy and disseminated encephalomyelitis. J Neurol Sci 2002; 195: 99-101.
50. Habib AA, Gilden D, Schmid DS, Safdieh JE. Varicella zoster virus meningitis with hypoglycorrhachia in the absence of rash and in an immunocompetent woman. J Neurovirol 2009; 15: 206-8.
51. Klein NC, McDermott B, Cunha BA. Varicella-zoster virus meningoencephalitis in an immunocompetent patient without a rash. Scand J Infect Dis 2010; 42: 631-3.
52. Gunson RN, Aitken C, Gilden D. A woman with acute headache and sacral dermatomal numbness. J Clin Virol 2011; 50: 191-3.
53. Moses H, Nagel MA, Gilden DH. Acute cerebellar ataxia in a 41year old woman. Lancet Neurol 2006; 5: 984-8.
54. Ratzka P, Schlachetzki JC, Bähr M, Nau R. Varicella zoster virus cerebellitis in a 66-year-old patient without herpes zoster. Lancet 2006; 367: 182.
55. Pina MA, Ara JR, Capablo JL, Omeñaca M. Myelitis and optic neuritis caused by varicella. Rev Neurol 1997; 25: 1575-6.
56. Celik Y, Tabak F, Mert A, Celik AD, Aktuǧlu Y. Transverse myelitis caused by varicella. Clin Neurol Neurosurg 2001; 103: 260-1.
57. Gilden DH, Beinlich BR, Rubinstien EM et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 1994; 44: 1818-23.
58. Kleinschmidt-DeMasters BK, Gilden DH. Varicella-zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med 2001; 125: 770-80.
59. Devinsky O, Cho ES, Petito CK, Price RW. Herpes zoster myelitis. Brain 1991; 114: 1181-96.
60. de Silva SM, Mark AS, Gilden DH et al. Zoster myelitis: improvement with antiviral therapy in two cases. Neurology 1996; 47: 929-31.
61. Chua HC, Tjia H, Sitoh YY. Concurrent myelitis and Guillain-Barre syndrome after varicella infection. Int J Clin Pract 2001; 55: 643-4.
62. Schvoerer E, Frechin V, Warter A et al. Persistent multiple pulmonary nodules in a nonimmunocompromised woman after varicella-related myelitis treated with acyclovir. J Clin Microbiol 2003; 41: 4904-5.
63. Orme HT, Smith G, Nagel MA, Bert RJ, Mickelson TS, Gilden DH. VZV spinal cord infarction identified by diffusion-weighted magnetic resonance imaging (DWI). Neurology 2007; 69: 398-400.
64. Bonfioli AA, Eller AW. Acute retinal necrosis. Semin Ophthalmol 2005; 20: 155-60.
65. Guex-Crosier Y, Rochat C, Herbort CP. Necrotizing herpetic retinopathies. A spectrum of herpes virus-induced diseases determined by the immune state of the host. Ocul Immunol Inflamm 1997; 5: 259-65.
66. Lewis JM, Nagae Y, Tano Y. Progressive outer retinal necrosis after bone marrow transplantation. Am J Ophthalmol 1996; 122: 892-5.
67. Franco-Paredes C, Bellehemeur T, Merchant A, Sanghi P, DiazGranados C, Rimland D. Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. AIDS 2002; 16: 1045-9.
68. Menerath JM, Gerard M, Laurichesse H et al. Bilateral acute retinal necrosis in a patient with acquired immunodeficiency syndrome. J Fr Ophtalmol 1995; 18: 625-33.
69. Johnston WH, Holland GN, Engstrom RE Jr, Rimmer S. Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993; 116: 42-50.
70. Moorthy RS, Weinberg DV, Teich SA et al. Management of varicella zoster virus retinitis in AIDS. Br J Ophthalmol 1997; 81: 189-94.
71. Austin RB. Progressive outer retinal necrosis syndrome: a comprehensive review of its clinical presentation, relationship to immune system status, and management. Clin Eye Vis Care 2000; 12: 119-29.
72. Gilden DH, Wright RR, Schneck SA, Gwaltney JM Jr, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol 1994; 35: 530-3.
73. Lewis GW. Zoster sine herpete. Br Med J 1958; 34: 418-21.
74. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986; 67: 1759-816.
75. Breuer J. VZV molecular epidemiology. Curr Top Microbiol Immunol 2010; 342: 15-42.
76. Breuer J, Whitley R. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 2007; 14(Suppl. 2): 25-9.
77. Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis 2008; 197(Suppl. 2): S39-40.
78. Umbach JL, Nagel MA, Cohrs RJ, Gilden DH, Cullen BR. Analysis of human α-herpesvirus microRNA expression in latently infected human trigeminal ganglia. J Virol 2009; 83: 10677-83.
79. Weinberg A, Zhang JH, Oxman MN et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200: 1068-77.
80. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis 1986; 154: 422-9.
81. Good RA, Zak SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 1956; 18: 109-49.
82. Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 1979; 26: 170-4.
83. Buchbinder SP, Katz MH, Hessol NA et al. Herpes oster and human immunodeficiency virus infection. J Infect Dis 1992; 166: 1153-6.
84. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.
85. Burke BL, Steele RW, Beard Ow, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142: 291-3.
86. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 2007; 25: 7087-93.
87. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 2003; 182: 40-52.
88. Hayward AR, Zerbe GO, Levin MJ. Clinical application of responder cell frequency estimates with four years of follow up. J Immunol Methods 1994; 170: 27-36.
89. Levin MJ, Barber D, Goldblatt E et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55years of age and older: duration of booster effect. J Infect Dis 1998; 178(Suppl. 1): S109-12.
90. Levin MJ, Oxman MN, Zhang JH et al. VZV-specific immune responses in elderly recipients of herpes zoster vaccine. J Infect Dis 2008; 197: 825-35.
91. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342: 341-57.
92. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(RR-5): 1-30.
93. Redman RL, Nader S, Zerboni L et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578-85.
94. Lin Y-H, Huang L-M, Chang I-S et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010; 28: 1217-20.
95. Hornberg J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145: 386-7.
96. Rothberg MB, Virapongse Am, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280-8.
97. Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4: 238-45.
98. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27: 1454-67.
99. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25: 8326-37.
100. Hurley LP, Harpaz R, Daley MF et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis 2008; 197(Suppl. 2): S216-23.
101. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine 2009; 27: 882-7.
102. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9-20.